{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:04:00Z","timestamp":1792649040407,"version":"4.5.0"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T00:00:00Z","timestamp":1669248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T00:00:00Z","timestamp":1669248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1038\/s41391-022-00609-3","type":"journal-article","created":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T19:57:28Z","timestamp":1669406248000},"page":"655-664","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Germline mutations in prostate cancer: a systematic review of the evidence for personalized medicine"],"prefix":"10.1038","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2908-6907","authenticated-orcid":false,"given":"Filippo","family":"Marino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6641-6154","authenticated-orcid":false,"given":"Angelo","family":"Totaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Gandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Bientinesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3418-5202","authenticated-orcid":false,"given":"Stefano","family":"Moretto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Gavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Pierconti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1750-2117","authenticated-orcid":false,"given":"Roberto","family":"Iacovelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PierFrancesco","family":"Bassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4640-8354","authenticated-orcid":false,"given":"Emilio","family":"Sacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,24]]},"reference":[{"key":"609_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. Ca Cancer J Clin. 2021;71:7\u201333. https:\/\/doi.org\/10.3322\/caac.21654","journal-title":"Ca Cancer J Clin"},{"key":"609_CR2","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1002\/cncr.20408","volume":"101","author":"DG Bostwick","year":"2004","unstructured":"Bostwick DG, Burke HB, Djakiew D, Euling S, Ho S, Landolph J, et al. Human prostate cancer risk factors. Cancer. 2004;101:2371\u20132490. https:\/\/doi.org\/10.1002\/cncr.20408","journal-title":"Cancer"},{"issue":"Apr","key":"609_CR3","doi-asserted-by":"publisher","first-page":"63","DOI":"10.14740\/wjon1191","volume":"10","author":"P Rawla","year":"2019","unstructured":"Rawla P. Epidemiology of Prostate Cancer. World J Oncol. 2019;10(Apr):63\u201389. https:\/\/doi.org\/10.14740\/wjon1191","journal-title":"World J Oncol"},{"key":"609_CR4","doi-asserted-by":"publisher","first-page":"s843","DOI":"10.1093\/ajcn\/86.3.843s","volume":"86","author":"AW Hsing","year":"2007","unstructured":"Hsing AW, Sakoda LC, Chua S. Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr. 2007;86:s843\u2013857. https:\/\/doi.org\/10.1093\/ajcn\/86.3.843s","journal-title":"Am J Clin Nutr"},{"key":"609_CR5","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/ijc.11466","volume":"107","author":"DW Bruner","year":"2003","unstructured":"Bruner DW, Moore D, Parlanti A, Dorgan J, Engstorm P. Relative risk of prostate cancer for men with affected relatives: systematic review and meta- analysis. Int J Cancer. 2003;107:797\u2013803. https:\/\/doi.org\/10.1002\/ijc.11466","journal-title":"Int J Cancer"},{"key":"609_CR6","doi-asserted-by":"publisher","first-page":"e27130","DOI":"10.1371\/journal.pone.0027130","volume":"6","author":"M Kici\u0144ski","year":"2011","unstructured":"Kici\u0144ski M, Vangronsveld J, Nawrot TS. An epidemiological reappraisal of the familial aggregation of prostate cancer: a meta-analysis. PLoS One. 2011;6:e27130 https:\/\/doi.org\/10.1371\/journal.pone.0027130","journal-title":"PLoS One"},{"key":"609_CR7","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.eururo.2005.01.016","volume":"47","author":"E Sacco","year":"2005","unstructured":"Sacco E, Prayer-Galetti T, Pinto F, Ciaccia M, Fracalanza S, Betto G, et al. Familial and hereditary prostate cancer by definition in an Italian surgical series: clinical features and outcome. Eur Urol. 2005;47:761\u2013768. https:\/\/doi.org\/10.1016\/j.eururo.2005.01.016","journal-title":"Eur Urol"},{"key":"609_CR8","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.2217\/fon.14.72","volume":"10","author":"C Mikropoulos","year":"2014","unstructured":"Mikropoulos C, Goh C, Leongamornlert D, Kote-Jarai Z, Eeles R. Translating genetic risk factors for prostate cancer to clinic: 2013 and beyond. Future Oncol. 2014;10:1679\u20131694. https:\/\/doi.org\/10.2217\/fon.14.72","journal-title":"Future Oncol"},{"key":"609_CR9","doi-asserted-by":"publisher","first-page":"a030379","DOI":"10.1101\/cshperspect.a030379","volume":"8","author":"A Dias","year":"2018","unstructured":"Dias A, Kote-Jarai Z, Mikropoulos C, Eeles R. Prostate Cancer Germline Variations and Implications for Screening and Treatment. Cold Spring Harb Perspect Med. 2018;8:a030379 https:\/\/doi.org\/10.1101\/cshperspect.a030379","journal-title":"Cold Spring Harb Perspect Med"},{"key":"609_CR10","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/s41588-018-0142-8","volume":"50","author":"FR Schumacher","year":"2018","unstructured":"Schumacher FR, Olama AAA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, et al. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat Genet. 2018;50:928\u2013936. https:\/\/doi.org\/10.1038\/s41588-018-0142-8","journal-title":"Nat Genet"},{"key":"609_CR11","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/s002-5347(17)35617-3","volume":"150","author":"BS Carter","year":"1993","unstructured":"Carter BS, Bova GS, Beaty TH, Steinberg GD, Childs B, Isaacs WB, et al. Hereditary prostate cancer: epidemiologic and clinical features. J Urol. 1993;150:797\u2013802. https:\/\/doi.org\/10.1016\/s002-5347(17)35617-3","journal-title":"J Urol"},{"key":"609_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.semradonc.2016.08.002","volume":"27","author":"TR Rebbeck","year":"2017","unstructured":"Rebbeck TR. Prostate Cancer Genetics: Variation by Race, Ethnicity, and Geography. Semin Radiat Oncol. 2017;27:3\u201310. https:\/\/doi.org\/10.1016\/j.semradonc.2016.08.002","journal-title":"Semin Radiat Oncol"},{"key":"609_CR13","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1111\/j.1464-410X.2010.10024.x","volume":"107","author":"S Madersbacher","year":"2011","unstructured":"Madersbacher S, Alcaraz A, Emberton M, Hammerer P, Ponholzer A, Schroder FH, et al. The influence of family history on prostate cancer risk: implications for clinical management. BJU Int. 2011;107:716\u2013721. https:\/\/doi.org\/10.1111\/j.1464-410X.2010.10024.x","journal-title":"BJU Int"},{"key":"609_CR14","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71 https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"609_CR15","doi-asserted-by":"publisher","first-page":"5910","DOI":"10.1158\/1078-0432.CCR-18-0370","volume":"24","author":"L Barber","year":"2018","unstructured":"Barber L, Gerke T, Markt SC, Peisch SF, Wilson KM, Ahearn T, et al. Family History of Breast or Prostate Cancer and Prostate Cancer Risk. Clin Cancer Res. 2018;24:5910\u20135917. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0370","journal-title":"Clin Cancer Res"},{"key":"609_CR16","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/gim.2013.193","volume":"16","author":"S Haraldsdottir","year":"2014","unstructured":"Haraldsdottir S, Hampel H, Wei L, Wu C, Frankel W, Bekaii-Saab T, et al. Prostate cancer incidence in males with Lynch syndrome. Genet Med. 2014;16:553\u2013557. https:\/\/doi.org\/10.1038\/gim.2013.193","journal-title":"Genet Med"},{"key":"609_CR17","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1158\/1055-9965.EPI-08-0317","volume":"17","author":"Z Kote-Jarai","year":"2008","unstructured":"Kote-Jarai Z, Easton DF, Stanford JL, Ostrander EA, Schleutker J, Ingles SA, et al. Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium. Cancer Epidemiol Biomark Prev. 2008;17:2052\u20132061. https:\/\/doi.org\/10.1158\/1055-9965.EPI-08-0317","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"609_CR18","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/ng.2560","volume":"45","author":"RA Eeles","year":"2013","unstructured":"Eeles RA, Olama AAA, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, et al. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet. 2013;45:385\u2013391. https:\/\/doi.org\/10.1038\/ng.2560. 391e1-2","journal-title":"Nat Genet"},{"key":"609_CR19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41588-020-00748-0","volume":"53","author":"DV Conti","year":"2021","unstructured":"Conti DV, Darst BF, Moss LC, Saunders EJ, Sheng X, Chou A, et al. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nat Genet. 2021;53:65\u201375. https:\/\/doi.org\/10.1038\/s41588-020-00748-0","journal-title":"Nat Genet"},{"key":"609_CR20","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.3390\/ijms22073753","volume":"22","author":"MT Vietri","year":"2021","unstructured":"Vietri MT, D\u2019Elia G, Caliendo G, Resse M, Casamassimi A, Passariello L, et al. Hereditary Prostate Cancer: Genes Related, Target Therapy and Prevention. Int J Mol Sci. 2021;22:3753 https:\/\/doi.org\/10.3390\/ijms22073753","journal-title":"Int J Mol Sci"},{"key":"609_CR21","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1056\/nejmoa1603144","volume":"375","author":"CC Pritchard","year":"2016","unstructured":"Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, et al. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N. Engl J Med. 2016;375:443\u2013453. https:\/\/doi.org\/10.1056\/nejmoa1603144","journal-title":"N. Engl J Med"},{"key":"609_CR22","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1038\/bjc.2014.30","volume":"110","author":"D Leongamornlert","year":"2014","unstructured":"Leongamornlert D, Saunders E, Dadaev T, Tymrakiewicz M, Goh C, Jugurnauth-Little S, et al. Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease. Br J Cancer. 2014;110:1663\u20131672. https:\/\/doi.org\/10.1038\/bjc.2014.30","journal-title":"Br J Cancer"},{"key":"609_CR23","doi-asserted-by":"publisher","first-page":"905","DOI":"10.3390\/medicina57090905","volume":"57","author":"YC Lee","year":"2021","unstructured":"Lee YC, Lee YL, Li CY. BRCA Genes and Related Cancers: A Meta-Analysis from Epidemiological Cohort Studies. Med (Kaunas). 2021;57:905 https:\/\/doi.org\/10.3390\/medicina57090905","journal-title":"Med (Kaunas)"},{"key":"609_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaoncol.2020.2134","volume":"6","author":"V Silvestri","year":"2020","unstructured":"Silvestri V, Lesli G, Barnes DR, Agnarsson BA, Aittomaki K, Alducci E, et al. Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1\/2(CIMBA). JAMA Once. 2020;6:1\u201313. https:\/\/doi.org\/10.1001\/jamaoncol.2020.2134","journal-title":"JAMA Once"},{"key":"609_CR25","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1038\/bjc.2012.146","volume":"106","author":"D Leongamornlert","year":"2012","unstructured":"Leongamornlert D, Mahmud N, Tymrakiewicz M, Saunders E, Dadaev T, Castro E, et al. Germline BRCA1 mutations increase prostate cancer risk. Br J Cancer. 2012;106:1697\u20131701. https:\/\/doi.org\/10.1038\/bjc.2012.146","journal-title":"Br J Cancer"},{"key":"609_CR26","doi-asserted-by":"publisher","unstructured":"Kote-Jarai Z, Leongamornlert D, Saunders E, Tymrakiewicz M, Castro E, Mahmud N et al. BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: Implications for genetic testing in prostate cancer patients. Br J Cancer. 105:1230\u20131234. https:\/\/doi.org\/10.1038\/bjc.2011.383.","DOI":"10.1038\/bjc.2011.383"},{"key":"609_CR27","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1158\/1078-0432.CCR-09-2871","volume":"16","author":"DJ Gallagher","year":"2010","unstructured":"Gallagher DJ, Gaudet MM, Pal P, Kirchhoff T, Balistreri L, Vora K, et al. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin Cancer Res. 2010;16:2115\u20132121. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-2871","journal-title":"Clin Cancer Res"},{"key":"609_CR28","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1002\/pros.22860","volume":"74","author":"C Maier","year":"2014","unstructured":"Maier C, Herkommer K, Luedeke M, Rinckleb A, Schrader M, Vogel W. Subgroups of familial and aggressive prostate cancer with considerable frequencies of BRCA2 mutations. Prostate. 2014;74:1444\u20131451. https:\/\/doi.org\/10.1002\/pros.22860","journal-title":"Prostate"},{"key":"609_CR29","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1200\/JCO.18.00358","volume":"37","author":"E Castro","year":"2019","unstructured":"Castro E, Romero-Laorden N, Del Pozo A, Lozano R, Medina A, Puente J, et al. PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2019;37:490\u2013503. https:\/\/doi.org\/10.1200\/JCO.18.00358","journal-title":"J Clin Oncol"},{"key":"609_CR30","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3892\/ijo.2019.4842","volume":"55","author":"SH Lang","year":"2019","unstructured":"Lang SH, Swift SL, White H, Misso K, Kleijnen J, Quek RGW. A systematic review of the prevalence of DNA damage response gene mutations in prostate cancer. Int J Oncol. 2019;55:597\u2013616. https:\/\/doi.org\/10.3892\/ijo.2019.4842","journal-title":"Int J Oncol"},{"key":"609_CR31","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.eururo.2016.11.033","volume":"71","author":"R Na","year":"2017","unstructured":"Na R, Zheng SL, Han M, Yu H, Jiang H, Jiang D, et al. Germline Mutations in ATM and BRCA1\/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. Eur Urol. 2017;71:740\u2013747. https:\/\/doi.org\/10.1016\/j.eururo.2016.11.033","journal-title":"Eur Urol"},{"key":"609_CR32","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.eururo.2018.09.021","volume":"75","author":"HB Carter","year":"2019","unstructured":"Carter HB, Helfand B, Mamawala M, Wu Y, Landis P, Yu H, et al. Germline Mutations in ATM and BRCA1\/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer. Eur Urol. 2019;75:743\u2013749. https:\/\/doi.org\/10.1016\/j.eururo.2018.09.021","journal-title":"Eur Urol"},{"key":"609_CR33","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/sj.bjc.6602007","volume":"91","author":"S Angele","year":"2004","unstructured":"Angele S, Falconer A, Edwards SM, Dork T, Bremer M, Moullan N, et al. ATM polymorphisms as risk factors for prostate cancer development. Br J Cancer. 2004;91:783\u2013787. https:\/\/doi.org\/10.1038\/sj.bjc.6602007","journal-title":"Br J Cancer"},{"key":"609_CR34","first-page":"15708","volume":"8","author":"Y Wang","year":"2015","unstructured":"Wang Y, Dai B, Ye D. CHEK2 mutation and risk of prostate cancer: a systematic review and meta-analysis. Int J Clin Exp Med. 2015;8:15708\u201315715.","journal-title":"Int J Clin Exp Med"},{"key":"609_CR35","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1200\/JCO.2015.63.3594","volume":"34","author":"C Naslund-Koch","year":"2016","unstructured":"Naslund-Koch C, Nordestgaard BG, Bojesen SE. Increased Risk for Other Cancers in Addition to Breast Cancer for CHEK2\u22171100delC Heterozygotes Estimated From the Copenhagen General Population Study. J Clin Oncol. 2016;34:1208\u20131216. https:\/\/doi.org\/10.1200\/JCO.2015.63.3594","journal-title":"J Clin Oncol"},{"key":"609_CR36","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/bjc.2012.486","volume":"108","author":"C Cybulski","year":"2013","unstructured":"Cybulski C, Wokolorczyk D, Kluzniak W, Jakubowska A, Gorski B, Gronwald J, et al. An inherited NBN mutations is associated with poor prognosis prostate cancer. Br J Cancer. 2013;108:461\u2013468. https:\/\/doi.org\/10.1038\/bjc.2012.486","journal-title":"Br J Cancer"},{"key":"609_CR37","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1002\/pros.23505","volume":"78","author":"Y Wu","year":"2018","unstructured":"Wu Y, Yu H, Zheng SL, Na R, Mamawala M, Landis T, et al. A comprehensive evaluation of CHEK2 germline mutations in men with prostate cancer. Prostate 2018;78:607\u2013615. https:\/\/doi.org\/10.1002\/pros.23505","journal-title":"Prostate"},{"key":"609_CR38","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2147\/TACG.S34116","volume":"6","author":"MC Southey","year":"2013","unstructured":"Southey MC, Teo ZL, Winship I. PALB2 and breast cancer: ready for clinical translation! Apple Clin Genet. 2013;6:43\u201352. https:\/\/doi.org\/10.2147\/TACG.S34116","journal-title":"Apple Clin Genet"},{"key":"609_CR39","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1001\/jamaoncol.2018.6760","volume":"5","author":"P Nicolosi","year":"2019","unstructured":"Nicolosi P, Ledet E, Yang S, Michakski S, Freschi B, O\u2019Leary E, et al. Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines. JAMA Oncol. 2019;5:523\u2013528. https:\/\/doi.org\/10.1001\/jamaoncol.2018.6760","journal-title":"JAMA Oncol"},{"key":"609_CR40","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/humu.21625","volume":"33","author":"ER Thompson","year":"2012","unstructured":"Thompson ER, Boyle SE, Johnson J, Ryland GL, Sawyer S, Choong DYH, et al. Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients. Hum Mutat. 2012;33:95\u201399. https:\/\/doi.org\/10.1002\/humu.21625","journal-title":"Hum Mutat"},{"key":"609_CR41","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.molcel.2009.10.020","volume":"36","author":"JD Norris","year":"2019","unstructured":"Norris JD, Chang CY, Wittmann BM, Kunder RS, Cui H, Fan D, et al. The Homeodomain Protein HOXB13 Regulates the Cellular Response to Androgens. Mol Cell. 2019;36:405\u2013416. https:\/\/doi.org\/10.1016\/j.molcel.2009.10.020","journal-title":"Mol Cell"},{"key":"609_CR42","doi-asserted-by":"publisher","first-page":"42312","DOI":"10.18632\/oncotarget.5994","volume":"6","author":"Q Cai","year":"2015","unstructured":"Cai Q, Wang X, Li X, Gong R, Guo X, Tang Y, et al. Germline HOXB13 p. Gly84Glu mutation and cancer susceptibility: A pooled analysis of 25 epidemiological studies with 145,257 participates. Oncotarget. 2015;6:42312\u201342321. https:\/\/doi.org\/10.18632\/oncotarget.5994","journal-title":"Oncotarget"},{"key":"609_CR43","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1056\/NEJMoa1110000","volume":"366","author":"CM Ewing","year":"2012","unstructured":"Ewing CM, Ray AM, Lange EM, Zuhlke KA, Robbins CM, Tembe WD, et al. Germline Mutations in HOXB13 and Prostate-Cancer Risk. N. Engl J Med. 2012;366:141\u2013149. https:\/\/doi.org\/10.1056\/NEJMoa1110000","journal-title":"N. Engl J Med"},{"key":"609_CR44","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.pharmthera.2018.04.004","volume":"189","author":"M Baretti","year":"2018","unstructured":"Baretti M, Le DT. DNA mismatch repair in cancer. Pharm Ther. 2018;189:45\u201362. https:\/\/doi.org\/10.1016\/j.pharmthera.2018.04.004","journal-title":"Pharm Ther"},{"key":"609_CR45","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/cge.12529.","volume":"87","author":"G Ponti","year":"2015","unstructured":"Ponti G, Castellsagu\u00e9 E, Ruini C, Percesepe A, Tomasi A. Mismatch repair genes founder mutations and cancer susceptibility in Lynch syndrome. Clin Genet. 2015;87:507\u2013516. https:\/\/doi.org\/10.1111\/cge.12529.","journal-title":"Clin Genet"},{"key":"609_CR46","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1158\/1055-9965.EPI-13-1165","volume":"23","author":"S Ryan","year":"2014","unstructured":"Ryan S, Jenkins MA, Win AK. Risk of prostate cancer in lynch syndrome: A systematic review and meta-Analysis. Cancer Epidemiol Biomark Prev. 2014;23:437\u2013449. https:\/\/doi.org\/10.1158\/1055-9965.EPI-13-1165","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"609_CR47","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.euo.2019.12.003","volume":"3","author":"Y Wu","year":"2020","unstructured":"Wu Y, Yu H, Li S, Wiley K, Zheng SL, LaDuca H, et al. Rare Germline Pathogenic Mutations of DNA Repair Genes Are Most Strongly Associated with Grade Group 5 Prostate Cancer. Eur Urol Oncol. 2020;3:224\u2013230. https:\/\/doi.org\/10.1016\/j.euo.2019.12.003","journal-title":"Eur Urol Oncol"},{"key":"609_CR48","doi-asserted-by":"publisher","first-page":"6863","DOI":"10.1158\/1078-0432.CCR-17-0955","volume":"23","author":"LB Guedes","year":"2017","unstructured":"Guedes LB, Antonarakis ES, Schweizer MT, Mirkheshti N, Almutairi F, Park JC, et al. MSH2 Loss in Primary Prostate Cancer. Clin Cancer Res. 2017;23:6863\u20136874. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0955","journal-title":"Clin Cancer Res"},{"key":"609_CR49","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.eururo.2020.07.038","volume":"79","author":"DJ Schaid","year":"2021","unstructured":"Schaid DJ, McDonnel SK, FitzGerald LM, DeRycke L, Fogarty Z, Giles GG, et al. Two-stage Study of Familial Prostate Cancer by Whole-exome Sequencing and Custom Capture Identifies 10 Novel Genes Associated with the Risk of Prostate Cancer. Eur Urol. 2021;79:353\u2013361. https:\/\/doi.org\/10.1016\/j.eururo.2020.07.038","journal-title":"Eur Urol"},{"key":"609_CR50","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.3390\/cancers13071495","volume":"13","author":"T Nguyen-Dumont","year":"2021","unstructured":"Nguyen-Dumont T, Dowty JG, Maclnnis RJ, Steen JA, Riaz M, Dugu\u00e9 PA, et al. Rare Germline Pathogenic Variants Identified by Multigene Panel Testing and the Risk of Aggressive Prostate Cancer. Cancers. 2021;13:1945 https:\/\/doi.org\/10.3390\/cancers13071495","journal-title":"Cancers"},{"key":"609_CR51","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1200\/JCO.2017.74.1173","volume":"36","author":"VN Giri","year":"2018","unstructured":"Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, et al. Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. J Clin Oncol. 2018;36:414\u2013424. https:\/\/doi.org\/10.1200\/JCO.2017.74.1173","journal-title":"J Clin Oncol"},{"key":"609_CR52","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.3390\/cancers13092154","volume":"13","author":"DK Doan","year":"2021","unstructured":"Doan DK, Schmidt KT, Chau CH, Figg WD, et al. Germline Genetics of Prostate Cancer: Prevalence of Risk Variants and Clinical Implications for Disease Management. Cancers. 2021;13:2154 https:\/\/doi.org\/10.3390\/cancers13092154","journal-title":"Cancers"},{"key":"609_CR53","first-page":"3868","volume":"13","author":"KS Allemailem","year":"2021","unstructured":"Allemailem KS, Almatroudi A, Alrumaihi F, Almansour NM, Aldakheel FM, Rather RA, et al. Single nucleotide polymorphisms (SNPs) in prostate cancer: its implications in diagnostics and therapeutics. Am J Transl Res. 2021;13:3868\u20133889.","journal-title":"Am J Transl Res"},{"key":"609_CR54","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1002\/gepi.20605","volume":"35","author":"RJ Macinnis","year":"2011","unstructured":"Macinnis RJ, Antoniou AC, Eeles RA, Severi G, Olama AAA, McGuffog L, et al. A risk prediction algorithm based on family history and common genetic variants: application to prostate cancer with potential clinical impact. Genet Epidemiol. 2011;35:549\u2013556. https:\/\/doi.org\/10.1002\/gepi.20605","journal-title":"Genet Epidemiol"},{"key":"609_CR55","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1016\/S1470-2045(15)00361-7","volume":"16","author":"H Gronberg","year":"2015","unstructured":"Gronberg H, Adolfsson J, Aly M, Nordstrom T, Wiklund P, Brandberg Y, et al. Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study. Lancet Oncol. 2015;16:1667\u20131676. https:\/\/doi.org\/10.1016\/S1470-2045(15)00361-7","journal-title":"Lancet Oncol"},{"key":"609_CR56","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1634\/theoncologist.2015-0336","volume":"21","author":"E Castro","year":"2016","unstructured":"Castro E, Mikropoulos C, Bancroft EK, Dadaev T, Goh C, Taylor N, et al. The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate Cancer. Oncologist 2016;21:716\u2013722. https:\/\/doi.org\/10.1634\/theoncologist.2015-0336","journal-title":"Oncologist"},{"key":"609_CR57","unstructured":"Eeles RA. The PROFILE Study: Germline Genetic Profiling: Correlation With Targeted Prostate Cancer Screening and Treatment. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02543905?term=nct02543905&draw=2&rank=1"},{"key":"609_CR58","unstructured":"R. A. Eeles, Institute of Cancer Research and Royal Marsden Hospital. \u201cThe IMPACT Study - Identification of Men With a Genetic Predisposition to Prostate Cancer. NCT00261456"},{"key":"609_CR59","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1016\/S1470-2045(21)00522-2","volume":"22","author":"EK Bancroft","year":"2021","unstructured":"Bancroft EK, Page EC, Brook MN, Thomas S, Taylor N, Pope J, et al. A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initiali results from an international prospective study. Lancet Oncol. 2021;22:1618\u20131631. https:\/\/doi.org\/10.1016\/S1470-2045(21)00522-2","journal-title":"Lancet Oncol"},{"key":"609_CR60","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.eururo.2014.01.003","volume":"66","author":"EK Bancroft","year":"2014","unstructured":"Bancroft EK, Page EC, Castro E, Lilja H, Vickers A, Sjoberg D, et al. Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. Eur Urol. 2014;66:489\u2013499. 10.106\/j.eururo.2014.01.003","journal-title":"Eur Urol"},{"key":"609_CR61","unstructured":"National Comprehensive Cancer Network Guidelines Version 2.2021. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf (accessed on February 2022)."},{"key":"609_CR62","unstructured":"European Association of Urology. Prostate Cancer guidelines. Available online: https:\/\/uroweb.org\/guidelines\/prostate-cancer (accessed on February 2022)."},{"key":"609_CR63","unstructured":"Parker C, Castro E, Fizazi K, Heindenreich A, Ost P, Procopio G et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Available: https:\/\/www.annalsofoncology.org\/action\/showPdf?pii=S0923-7534%2820%2939898-7"},{"key":"609_CR64","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1200\/JCO.2015.65.7759","volume":"34","author":"RC Chen","year":"2016","unstructured":"Chen RC, Rumble BR, Loblaw DA, Finelli A, Ehdaie B, Cooperberg MR, et al. Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement. J Clin Oncol. 2016;34:2182\u20132190. https:\/\/doi.org\/10.1200\/JCO.2015.65.7759","journal-title":"J Clin Oncol"},{"key":"609_CR65","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/bju.13862","volume":"120","author":"JM Telang","year":"2017","unstructured":"Telang JM, Lane BR, Cher ML, Miller DC, Dupree JM. Prostate cancer family history and eligibility for active surveillance: a systematic review of the literature. BJU Int. 2017;120:464\u2013467. https:\/\/doi.org\/10.1111\/bju.13862","journal-title":"BJU Int"},{"key":"609_CR66","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1097\/ju.0000000000001027","volume":"204","author":"D Halstuch","year":"2020","unstructured":"Halstuch D, Ber Y, Kedar D, Golan S, Baniel J, Margel D. Short-term outcomes of active surveillance for low risk prostate cancer among men with germline DNA repair gene mutations. J Urol. 2020;204:707\u2013713. https:\/\/doi.org\/10.1097\/ju.0000000000001027","journal-title":"J Urol"},{"key":"609_CR67","unstructured":"De Bono J. TOPARP: A Phase II Trial of Olaparib in Patients With Advanced Castration Resistant Prostate Cancer. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01682772"},{"key":"609_CR68","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1470-2045(19)30684-9","volume":"21","author":"J Mateo","year":"2020","unstructured":"Mateo J, Porta N, Bianchini D, McGovern U, Elliott T, Jones R, et al. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP - B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2020;21:162\u2013174. https:\/\/doi.org\/10.1016\/S1470-2045(19)30684-9","journal-title":"Lancet Oncol"},{"key":"609_CR69","unstructured":"De Bono J, Hussain M. Study of Olaparib (Lynparza\u2122) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02987543"},{"key":"609_CR70","unstructured":"A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON2). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02952534"},{"key":"609_CR71","unstructured":"An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies (Galahad). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02854436"},{"key":"609_CR72","unstructured":"De Bono J. A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03148795?term=NCT03148795&draw=2&rank=1"},{"key":"609_CR73","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","volume":"373","author":"J Mateo","year":"2015","unstructured":"Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, et al. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N. Engl J Med. 2015;373:1697\u20131708. https:\/\/doi.org\/10.1056\/NEJMoa1506859","journal-title":"N. Engl J Med"},{"key":"609_CR74","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J De Bono","year":"2020","unstructured":"De Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020;382:2091\u20132102. https:\/\/doi.org\/10.1056\/NEJMoa1911440","journal-title":"N Engl J Med"},{"key":"609_CR75","doi-asserted-by":"publisher","first-page":"3763","DOI":"10.1200\/JCO.20.01035","volume":"38","author":"W Adiba","year":"2020","unstructured":"Adiba W, Patnaik A, Campbell D, Shapiro J, Bryce AH, McDermott R, et al. Rucaparib in Men With Metastatic Castration Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration. J Clin Oncol. 2020;38:3763\u20133772. https:\/\/doi.org\/10.1200\/JCO.20.01035","journal-title":"J Clin Oncol"},{"key":"609_CR76","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1158\/1078-0432.CCR-20-0394","volume":"26","author":"W Abida","year":"2020","unstructured":"Abida W, Campbell D, Patnaik A, Shapiro JD, Sautois B, Vogelzang NJ, et al. Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis from the Phase II TRITON2 Study. Clin Cancer Res. 2020;26:2487\u20132496. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0394","journal-title":"Clin Cancer Res"},{"key":"609_CR77","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/S1470-2045(21)00757-9","volume":"23","author":"MR Smith","year":"2022","unstructured":"Smith MR, Scher HI, Sandhu S, Efstathiou E, Lara PN Jr. Yu EY, et al. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD); a multicentre, open-label, phase 2 trial. Lancet Oncol. 2022;23:362\u2013373. https:\/\/doi.org\/10.1016\/S1470-2045(21)00757-9","journal-title":"Lancet Oncol"},{"key":"609_CR78","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/S1470-2045(21)00376-4","volume":"22","author":"JS De Bono","year":"2021","unstructured":"De Bono JS, Mehra N, Scagliotti GV, Castro E, Dorff T, Stirling A, et al. Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial. Lancet Once. 2021;22:1250\u20131264. https:\/\/doi.org\/10.1016\/S1470-2045(21)00376-4","journal-title":"Lancet Once"},{"key":"609_CR79","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le DT, Durham JN, Smith KN, Wang H, Barlett BR, Aulakh LK, et al. Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357:409\u2013413. https:\/\/doi.org\/10.1126\/science.aan6733","journal-title":"Science"},{"key":"609_CR80","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.eururo.2018.10.009","volume":"75","author":"ES Antonarakis","year":"2019","unstructured":"Antonarakis ES, Shaukat F, Velho PI, Kaur H, Shenderov E, Pardoll DM, et al. Clinical Features and Therapeutic Outcomes in Men with Advanced Prostate Cancer and DNA Mismatch Repair Gene Mutations. Eur Urol. 2019;75:378\u2013382. https:\/\/doi.org\/10.1016\/j.eururo.2018.10.009","journal-title":"Eur Urol"},{"key":"609_CR81","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1001\/jamaoncol.2018.5801","volume":"5","author":"W Abida","year":"2019","unstructured":"Abida W, Cheng ML, Armenia J, Middha S, Autio KA, Vargas HA, et al. Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. JAMA Once. 2019;5:471\u2013478. https:\/\/doi.org\/10.1001\/jamaoncol.2018.5801","journal-title":"JAMA Once"},{"key":"609_CR82","doi-asserted-by":"publisher","first-page":"e001065.","DOI":"10.1136\/jitc-2020-001065","volume":"8","author":"P Barata","year":"2020","unstructured":"Barata P, Agarwal N, Nussenzveig R, Gerendash B, Jaeger E, Hatton W, et al. Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA. J Immunother Cancer. 2020;8:e001065. https:\/\/doi.org\/10.1136\/jitc-2020-001065","journal-title":"J Immunother Cancer"},{"key":"609_CR83","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1200\/po.19.00346","volume":"4","author":"JM Mota","year":"2020","unstructured":"Mota JM, Barnett E, Nauseef JT, Nguyen B, Stopsack KH, Wibmer A, et al. Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations. JCO Precis Oncol. 2020;4:355\u2013366. https:\/\/doi.org\/10.1200\/po.19.00346","journal-title":"JCO Precis Oncol"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-022-00609-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-022-00609-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-022-00609-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T08:02:41Z","timestamp":1699603361000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-022-00609-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,24]]},"references-count":83,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["609"],"URL":"https:\/\/doi.org\/10.1038\/s41391-022-00609-3","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,24]]},"assertion":[{"value":"26 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}